Tuesday, 30 August 2016

Dyslipidemia Drugs Market to Decline at 10.30% CAGR between 2015 and 2023

The research report, titled “Dyslipidemia Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023,” states that the impending patent expiry of blockbuster dyslipidemia drugs is likely to dilute profit margins of drugmakers in this market. This factor is expected to influence the global dyslipidemia drugs market negatively over the forecast period, resulting in a decline in its market valuation.

Transparency Market Research (TMR) has recently published a market study on the global market for dyslipidemia drugs and projected that this market will decline at a CAGR of 10.30% during the period from 2015 to 2023. The worldwide dyslipidemia drugs market stood at US$17.9 bn in 2014. Analysts at TMR estimate the overall value of the market to reach US$6.9 bn by the end of the forecast period.

The delay in the approval of new dyslipidemia drugs is also projected to hamper the growth of this market significantly in the coming years. However, the increasing patient pool, suffering from an excess of cholesterol and other defects caused by triglyceride, is likely to drive the demand for dyslipidemia drugs in the near future, states the study.

Bile acid resins, statins, niacins, omega-3 fatty acid derivatives, fibric acid, cholesterol absorption inhibitors, and combination drugs are the major therapeutics available in the global dyslipidemia drugs market. As per the report, the statins segment led the overall market in 2014 and is projected to retain its position during the forecast period.

The report segments the global market for dyslipidemia drugs into Europe, Asia Pacific, North America, Latin America, and the Middle East and Africa. North America among all, dominated the worldwide dyslipidemia drugs market in 2014. Favorable government policies for drug approval in this region, together with the continual rise in the prevalence of dyslipidemia, have substantially propelled the North America market for dyslipidemia drugs.

The same year, Europe occupied the second position in the worldwide dyslipidemia drugs market with a share of around 25%. The higher disposable income of consumers in the region allows them to afford branded formulation. This in turn provides favorable growth opportunities to drug manufacturers, in this regional market, states the report.

In Europe, Germany was the biggest domestic dyslipidemia drugs market in 2014. It is likely to maintain its dominance over the forecast period, owing to the increasing incidence of dyslipidemia, resulting in the high demand for dyslipidemia drugs.

Abbott Laboratories, Amgen Inc., AstraZeneca Plc, Bayer AG, Mylan N.V., Bristol-Myers Squibb Co., Novartis AG, Pfizer Inc., Merck & Co. Inc., Shionogi & Co. Ltd., Teva Pharmaceutical Industries Ltd., and Takeda Pharmaceutical Co. Ltd. are some of the major participants in the global dyslipidemia drugs market, mentioned in this report.

Browse Research Report on Global Dyslipidemia Drugs Market:

Monday, 29 August 2016

Prefilled Syringes Market Observes Shift from Glass to Polymers for Manufacturing Syringe Barrels

Transparency Market Research has recently published a report on the global prefilled syringes market. The report, titled “Prefilled Syringes Market - Global Industry Analysis, Size, Volume, Share, Growth, Trends and Forecast, 2013 - 2019,” offers an insightful study on the global prefilled syringes market and projects the expansion of the market at a CAGR of 13.3% during the period from 2013 to 2019. The global prefilled syringes market stood at a valuation of US$2.09 bn in 2012 and is anticipated to be worth US$4.98 bn by 2019. The report identifies the key factors impacting the growth of the market and profiles some of the prominent players in the market. 

Download Exclusive Global Strategic Business Report:

In the injectable drug delivery devices market, the prefilled syringes segment is one of the fastest growing segments. Various benefits of prefilled syringes including reduced risk of cross contamination, and ease of handling and administration have led to their increased demand in the market. 

The report states that the continuous growth in the injectable drugs market worldwide has boosted the growth of the global prefilled syringes market. The advantages of prefilled syringes over conventional vials and syringe packing systems have supported the market’s growth. Increase in the demand for point-of-care administration and technological advancements in the manufacturing of prefilled syringes are expected to augment the growth of the market during the forecast horizon. However, the introduction of alternative drug delivery methods might hamper the growth of the market.

On the basis of material used for the manufacturing of barrel of the syringe, prefilled syringes can be classified into two types: Plastic prefilled syringes and glass prefilled syringes. The glass prefilled syringes are considered as the standard syringes in the industry and hence, this syringe segment dominates the overall market in terms of volume and revenue. However, the market is witnessing the extensive utilization of polymer or plastic by syringe manufacturers.

Key regions in the global prefilled syringes market are Europe, North America, Asia Pacific, and Rest of the World. In terms of revenue and volume, Europe has emerged as the largest regional market for prefilled syringes. During the forecast horizon, North America is projected to witness expansion at a CAGR of 15%. The robust growth of the North America prefilled syringes market can be attributed to the increased shift from vials to prefilled syringes and the presence of some of the key drug manufacturers in the region. While Asia Pacific has been one of the late adopters of prefilled syringes, the region is anticipated to grow rapidly owing to the presence of a large patient pool and the growing awareness about prefilled syringes. 

Some of the key players in the global prefilled syringes market are Schott AG, Gerresheimer AG, Becton, Dickinson and Company, Nipro Corporation, Baxter International Inc., Ypsomed Holding AG, Stevanato Group, Unilife Corporation, Bespak, West Pharmaceutical Services, Inc., and Vetter Pharma International GmbH. These players have been profiled on the basis of company overview, product portfolio, and financial overview. For the new and existing players in the market, the report offers strategic recommendations such as the adoption of polymer technology for the manufacturing of prefilled syringes and investments in the emerging markets in North America.

Browse Research Report on Global Prefilled Syringes Market:

Hospital Clinical Chemistry and Immunodiagnostics Market Analysis, Trends and Share - 2020

The global market for hospital clinical chemistry and immunodiagnostics is examined in a recent market research report by Transparency Market Research. The report, titled “Hospital Clinical Chemistry and Immunodiagnostics Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2020,” analyzes the market on the basis of key segments, geographies, and trends.

The market has witnessed vast advances in the past few years, resulting in the development of diagnostic technologies such as spectrophotometry, molecular diagnostics, measurement of enzyme activities, electrophoresis, and separation of molecules. Developments across these specialty segments have significantly changed the way and the extent to which clinicians can diagnose, prevent, and treat a variety of diseases.

Diseases that are generally diagnosed with the help of clinical chemistry include diabetes, viral and bacterial infections, thyroid issues, cardiovascular conditions, and cystic fibrosis in newborn babies.
The varieties of tests that come under the purview of immunodiagnostics include Enzyme-Linked Immuno Sorbent Assay or ELISA and radioimmunoassay. Hospital clinical chemistry includes tests undertaken in the fields such as routine chemistry, endocrinology, drug monitoring, special chemistry, toxicology, and urinalysis.

The report analyzes detailed market data for these end-use segments of the global hospital clinical chemistry and immunodiagnostics market across key geographies, gathering qualitative and quantitative information elucidating the past, present, and the potential future state of these segments. For ease of understanding, the global market is covered by segmenting it into geographical markets such as North America, Asia Pacific, Europe, and Rest of the World.

The market has reached maturity in developed regions such as Europe and North America. Factors supporting growth of these regional markets include the easy availability of advanced and innovative medical technologies across healthcare settings, presence of some of world’s largest healthcare companies, and vast investments towards research and development activities. The vast rise in global prevalence of a number of infectious and chronic diseases has also led to the increased demand for a variety of reliable and advanced diagnostic tests, thus driving the market.

Developments in the field have also resulted in significant reduction in the complexity and duration of immunoassays, thereby bolstering market’s future growth prospects. Asia Pacific is a highly lucrative regional market for clinical chemistry and immunodiagnostics owing to the presence of a large patient pool and rising healthcare expenditures.

Factors such as advancements in diagnostic modalities, intense competition, and automation are leading to the development of vast growth opportunities. Some of the key vendors operating in the market are F. Hoffmann-La Roche Ltd., Abbott, Danaher Corporation, Siemens AG, Bio-Rad Laboratories, Inc., and Thermo Fisher Scientific, Inc.

Browse Research Report on Global Hospital Clinical Chemistry and Immunodiagnostics Market:

Friday, 26 August 2016

Government Efforts Crucial in Increasing the Availability of Teleradiology Technology Market in Asia Pacific

The global teleradiology market is expected to expand at a favorable 11.3% CAGR over the period between 2015 and 2023, and rise from a valuation of US$1,354.6 mn in 2014 to US$3,632.6 mn in 2023.

Download Complete Healthcare Analytical Brochure: 

The highly fragmented market for teleradiology features the presence of a large number of regional players, with the exception of some large companies with international presence, such as vRad, Inc., Radiology Reporting Online,  and USA Rad. North America and Europe, the regions with some of the largest vendors in the global teleradiology market, will be the key enablers of teleradiology practices across the world and play a central role in the overall development of the global market, notes a recent report by Transparency Market Research (TMR).

Acquisitions of small, regional players, and long-term contracts with remotely located community hospitals and other healthcare service providers, especially across emerging markets such as Asia Pacific and Latin America, will allow teleradiology companies to expand their global footprint. Although less in number than in the European market, teleradiology companies in North America will contribute the largest share in the overall revenues of the global teleradiology market from 2015 through 2023, thanks to their global presence.

Rise in Healthcare Expenditure and Improved Healthcare Infrastructure to Enable Widespread Adoption of Teleradiology

The vast improvement in telecommunication networks, enhanced data transfer speeds, and improved digital infrastructure of remote parts of the world has revolutionized the global teleradiology market in the past few years. In the next few years as well, developments across the data transmission field will be prove to be a major driver of the global teleradiology market, allowing its evolution from an ancillary radiology discipline to a mainstream practice.

Radiology is a cost-intensive diagnostic modality owing to the high prices of the technologically advanced medical imaging machines central to the field. This factor, in combination with the factor of unavailability of broadband networks in urban dwellings has remained one of the toughest challenges for the teleradiology market in the past years. However, substantial rise in healthcare expenditures and widened broadband networks in the past few years have enabled the widespread expansion of teleradiology practices on a global front. These factors have especially allowed the teleradiology market in extending its reach to emerging economies such as Latin America and Asia Pacific, considered to be the regional markets with the most lucrative growth opportunities.

Asia Pacific to Provide Most Attractive Growth Opportunities

North America is currently the leading regional market for teleradiology and is expected to provide considerable growth opportunities over the next few years as well. The market in the region will be driven by the digitally advanced healthcare infrastructures, integration of teleradiology services in the workflow of a vast number of medical imaging service providers, and high healthcare awareness among the population. The rising prevalence of a number of cancers in the region has also led to an increased need for effective teleradiology services in the region.

Nevertheless, Asia Pacific will provide the most lucrative growth opportunities for the global teleradiology market in the coming years. Factors fueling demand for teleradiology services in the region will be the rising expenditure on health and wellbeing, improving healthcare infrastructure, and widening network of high-speed broadband services.

Browse Research Report on Global Teleradiology Market:

Monday, 22 August 2016

Demand for Dermatology Diagnostic Devices and Therapeutics to Rise in Response to Growing Prevalence of Acute Skin Conditions, says TMR

Demonstrating the presence of a considerably large number of companies, the vendor landscape in the global market for dermatology diagnostic devices and therapeutics is highly competitive. As per Transparency Market Research, Afga Gevart, Michelson Diagnostic Ltd., and Strata Skin Sciences have emerged as the top players in the dermatology diagnostics devices market. In 2014, these companies together accounted for a share of about 42% in the market. 

View exclusive Global strategic Business report :

Likewise, the leading companies in the global dermatology therapeutics market include AbbVie, Janssen, GSK, Galderma, Valeant, and Novartis. These companies together held approximately 76% of the market with AbbVie accounting for the largest share. “With an aim to gain competitive advantage, major companies in the dermatology therapeutics market are capitalizing on easy availability of products and superior distribution channel,” says a lead analyst at TMR.

Demand for Dermatology Devices and Therapeutic to Rise in Response to Increasing Incidence of Skin Diseases 

Growth prospects for the dermatology diagnostic devices and therapeutics market seem quite positive. Due to the increasing incidence of acute skin disorders, demand for dermatology devices and therapeutics is poised to surge at a rapid pace in the forthcoming years. Skin conditions such as acne, psoriasis, eczema, rosacea, pruritus, cell carcinoma, and dermatitis have become increasingly prevalent worldwide, thus necessitating efficient treatment modalities. As per TMR, such skin conditions can occur at any age and presently affects about 30% to 70% of the global population. This creates high demand for dermatology treatment, which translates into intense competition among leading players in the market. Besides this, increasing geriatric population also boosts demand for dermatology diagnostic devices and therapeutics. 

“Despite witnessing favorable growth opportunities, demand for dermatology devices and effective therapeutics is likely to be hampered by the implementation of stringent regulations such as Affordable Care Act,” said an analyst at TMR. Patent expirations also pose major threat to the leading manufacturers of dermatology devices and drugs. Nevertheless, the growing population and the increasing willingness among people to spend on aesthetically enhancing their beauty will keep the demand for dermatology devices and therapeutics high between 2015 and 2023.

North America Presents Most Lucrative Prospects for Dermatology Diagnostic Devices and Therapeutics Marke

Regionally, North America has emerged as the largest market for dermatological diagnostic devices and therapeutics. In the last few years, the number of patients complaining skin diseases such as melanoma, impetigo, and psoriasis has considerably increased in North America. This resulted in high sales of dermatology devices and therapeutics in the region. As per TMR, North America accounted for the dominant share of 43.8% in the global market in 2014. 

Demand for dermatology treatment is also expected to significantly increase in Southeast Asia, as this region witnesses a high prevalence of skin disorders. While Europe has emerged as the second largest market for dermatology diagnostic devices and therapeutics, the market in Asia Pacific is likely to exhibit the fastest growth. 

By product, the demand for imaging equipment is rising at a high pace in the dermatology diagnostics market. The segment held the largest share in the market in 2014. The high price of imaging equipment has helped the segment in gaining lead in the market. However, as per TMR, the demand for high sensitivity imaging equipment is expected to increase at a faster pace in the forecast period. 

The global dermatology diagnostic devices market is likely to exhibit a CAGR of 6.9% between 2015 and 2023. The market stood at US$0.6 bn in 2014 and is expected to reach US$1 bn by the end of 2023. The global market for dermatology therapeutics will however show a moderate CAGR of 1.9% during the forecast period. As per TMR, the market is expected to reach US$20.1 bn in 2023, from a valuation of US$17.5 bn in 2014.

Browse Research Report on Global Dermatology Diagnostic Devices and Therapeutics Market:

Thursday, 18 August 2016

PAP and Paracetamol Market set to Flourish due to Growing Awareness of Side Effects of Medications

Some of the leading players in the global PAP (para-aminophenol) and paracetamol market are Mallinckrodt, Anqiu Lu'an Pharmaceutical Co., Ltd., Granules India, and Taixing Yangzi Pharm Chemical Co., Ltd. The highly fragmented markets will witness companies stepping up their supply capabilities through well-established distribution channels and influential marketing strategies to remain relevant, observes Transparency Market Research in a new report. 

You can download a sample report for free:

“Investments in emerging economies of Asia Pacific at this juncture will help reduce operating costs due to cheap labor and a well-equipped infrastructure. The domestic markets in Asia Pacific are showing promise of growth as well,” states the lead author of this leading research report. Expanding production capacities and providing sophisticated quality of products by limiting the range of products offered to focus on core competencies will prove to be an important move for players to tackle the cut-throat competition.
Need Pain Management Drives PAP and Paracetamol Market

The market drivers for PAP and paracetamol are closely interlinked as 80% of the PAP produced across the globe is used in production of paracetamol. Thus, the overall increase in the production of paracetamol, a commonly used analgesic, is driving the global PAP market. The other increasing end uses of PAP in sulfide dyes, azo dyes, fur dyes, photographic developers, and rubber antioxidants are propelling the consumption of PAP. The high incidence of pain-related diseases and conditions have also increased the uptake of paracetamol in recent years, creating a direct impact on the sales of PAP.

The low production costs in emerging countries such as China and India have made them the focal point of chemical manufacturing activities. The evolving nature of these manufacturing units with diversified production capabilities have also contributed towards high utilization of PAP. The accelerated pace of manufacturing agro-chemicals, pharmaceuticals, and dyes amongst others will collectively lead to growing demand for PAP during the forecast period.

Solvent-free Synthesizing Challenges PAP Market

The shifting focus on synthesizing paracetamol without solvents is expected to hamper the usage of PAP in manufacturing processes, thereby restraining the growth of PAP market in the coming years. Furthermore, growing awareness amongst consumers about side-effects of analgesics is also create a negative sentiment in the paracetamol market. However, efforts channelized towards forward and backward integration will organize businesses in a far more efficient manner.

Asia Pacific Makes Most of Production Opportunities to Maintain Lead

According to the research report, the global paracetamol market is expected to reach US$1,049.7 mn by 2022 as compared to its valuation of US$900.2 mn in 2014. On the other hand, the para-aminophenol market, which was valued at US$452.7 mn in 2014 is expected to reach US$709.2 mn by 2022. Analysts have identified North America as the largest geographical segment in both the markets with the PAP market here poised to reach revenues of US$295.3 mn by 2022 and paracetamol representing an opportunity worth US$437.1 mn by 2022. Meanwhile, Asia Pacific is expected to take up the opportunity of highest production of paracetamol, thus registering a CAGR of 1.9% during the forecast period. This region will also take lead in the PAP market with a steady CAGR of 8.1% between 2014 and 2022.

This review is based on Transparency Market Research’s report, titled “PAP and Paracetamol Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2014 - 2022.”

Browse Research Report on Global PAP and Paracetamol Market:

Wednesday, 17 August 2016

Sperm Bank Market Global Industry Landscape and Opportunities 2024

Global Sperm Bank Market: Overview and Dynamics

The global market for sperm banks has been witnessing increasing growth since the last few recent years, primarily owing to the surge in social acceptance and awareness among the general population. Rise in the number of young sperm donors, legalization of and increase in same-sex marriages, various technological advancements in the field of assistive reproduction, and strong support on the part of governments toward donor offspring and sperm donors are also projected to boost the sperm bank market. However, this market continues to be challenged by the negative mindset toward sperm donation, high cost of artificial insemination and assistive reproduction, and several government regulations in developing and underdeveloped countries.

Sperm donors can be of several types: Directed donor, client donor, anonymous donor, and known donor. Sperm banks offer a range of services such as sperm storage, genetic consultation, sperm donations, and semen analysis for a variety of end users such as pre-vasectomy patients, police officers, high-impact athletes, cancer patients, military personnel, firefighters, and transgender people.

The report on the global sperm bank market offers clients an in-depth assessment of the emergence, popularity, need, and forecast of sperm banks across the globe. Various factors driving the demand for sperm banks, those that act as impediments to the market growth, and several policies and laws impacting sperm donation as a service have been carefully studied in the report. The research also highlights the present status of the vendor landscape, identifying the major players competing at a global level and evaluating their performance over the years.

Global Sperm Bank Market: Region-wise Outlook

The global sperm bank market has been segmented on the basis of geography into North America, Europe, Asia Pacific, and Rest of the World. Considering that North America has the highest number of sperm banks with the highest number of licensed labs, this regional market for sperm banks is one of the largest in the world. Other factors such as the availability of advanced assisted reproductive technologies, higher disposable income and spending on health care, growing awareness among the general population, and high rate of miscarriages have also significantly contributed to the growth of the sperm bank market in North America.

Europe is a growing market for sperm banks given the surging demand for the same. However, the high unmet need is presently the only lucrative attraction for market players in the region, since there is a severe shortage of sperm donors as compared to the increasing demand. Countries such as the U.K. have been investing in new and innovative advertising plans to increase awareness among the male population in the country and encourage them to actively participate in sperm donation.

The sperm bank market in Asia Pacific holds immense opportunities owing to a high rate of infertility and miscarriages in the region. In China, For instance, the alarming levels of air pollution in China have caused a decrease in sperm quality, count, and motility, thereby driving the demand for sperm donors and sperm banks.

Global Sperm Bank Market: Vendor Landscape Assessment

The vendor landscape of the global sperm bank is consolidated to an extent, considering very few large players control a majority of the overall sperm bank market. New England Cryogenic Center Inc., Cryos International Sperm Bank, FairFax Cryobank, and Androcryos are currently the most prominent and dominant companies operating in the global sperm bank market. Orlando, a Florida-based Cyros International Sperm Bank, is presently one of the largest sperm banks in the world. With an additional base set up in Mumbai, India in 2008, Cryos has been approved by the U.S. Food and Drug Administration as well as the Indian Council of Medical Research. Recognizing the immense potential that the sperm bank market possesses, an increasing number of players have been undergoing continuous upgrade to withstand the competition presented by industry giants.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Browse Research Report on Global Sperm Bank Market:

Monday, 15 August 2016

The Global Medical Imaging Reagents Market - Growth Estimates and Analysis

Medical imaging reagents find applications in determining whether a tumor is benign or malignant and help in the detection of metastatic cancerous sites in the body with high accuracy. Medical imaging reagents are chemicals that play a vital role in biotechnology medical, diagnostic, pharmaceuticals, and life science industries. High demand from various end-users is likely to fuel the growth of the global medical imaging reagents market.

As per a research report by Transparency Market Research (TMR), the valuation of global medical imaging reagents market was US$10.3 bn in 2012 and is anticipated to reach US$18.5 bn by 2019, growing at a considerable CAGR of 8.80% between 2013 and 2019.

Why are more clinicians and healthcare providers opting for medical imaging reagents?

The growing demand for diagnostic and functional imaging technologies coupled with the rising prevalence of cancer and cardiac disorders has led to increased uptake of medical imaging reagents by clinicians and healthcare. Moreover, growing concerns for the safety of patient and increased applications of advanced medical reagents are likely to generate notable growth opportunities for the global medical imaging reagents market.

Furthermore, the incidence rate of various disorders associated with cardiovascular and neurological symptoms increases with the growing geriatric population. This demographic trend is likely to spur the growth of the global medical imaging reagents market.

Why is there a considerable adoption rate of substitutes of medical imaging reagents? 

Despite their safety, medical imaging reagents fail to provide inexpensive solutions due to their high development cost. Unfavorable reimbursement policies are further preventing patients from undergoing medical imaging. The insurance policies do not cover medical imaging considering that the method is only meant for diagnosing cancer and not curing it. Moreover, the shortage of supplies in response to the growing demand is impeding the growth of the global medical imaging reagents market.

Another factor that is negatively influencing the growth of the global medical imaging reagents market is the low level of awareness amongst the patient pool in the emerging nations. Furthermore, the stringent regulations and high capital investment induce high entry and exit barriers for the new entrants.  All these factors are creating bottlenecks in the growth of the global medical imaging reagents market.

What are the most important trends affecting the growth of the global medical imaging reagents market?

According to a report by the World Health organization (WHO), the number of new cancer cases is anticipated to increase by about 70% over the next 2 decades. The growing prevalence of cancer has promoted the application of global medical imaging reagents. The high growth rate of the drug discovery and development segment can be attributed to a large number of applications of medical imaging reagents in pre-clinical studies. However, the diagnostics application segment will be the leading segment in the overall market by revenue due to the augmenting patient base of chronic disorders such as neurological diseases, cancers, and cardiovascular diseases. 

Rapid growth in the demand for nuclear reagents can be attributed to the augmented adoption of localized tracers and nuclear medicine. By technology, the nanoparticles segment is anticipated to register substantial growth owing to the large-scale applicability of these technologies along with a wide scope of research and development associated with their application areas.

On the basis of geography, the global medical imaging reagents market is categorized into Asia Pacific, Europe, North America, and Rest of the World. Asia Pacific emerges to be a rapidly growing market due to the increasing demand for medical imaging reagents coupled with the fast developing economic structure. On the flip side, North America leads the overall market due to the high incidence of cardiovascular and neurological diseases and cancer in the region.

Browse Research Report on Global Medical Imaging Reagents Market:

Monday, 8 August 2016

Ophthalmic Drugs Market to Reach US$21.6 bn by 2018 due to High Incidence of Eye-related Disorders amongst Geriatrics

The increasing number of cases of retinal disorders has compelled ophthalmic drug companies to shift their focus towards the implementation of combination therapies, reports Transparency Market Research. Due to the lack of market fragmentation, the existing companies are initiating research and development investments regarding product innovation. The leading companies in the global ophthalmic drugs market are Novartis (Alcon), Roche, Pfizer, Santen, Allergan, and Merck. These companies accounted for close to 70% of the global ophthalmic market in 2012. 

The leading companies in the global ophthalmic drugs market are engaging in numerous mergers and acquisitions as they seek growth opportunities. The mergers and acquisitions are based on tactical business requirements, which include product portfolio expansion, business expansion, geographical expansion, and expansion of research and development channels. The growth trajectory of the ophthalmic drugs market will depend on how companies capitalize on opportunities such as the growing government initiatives for healthcare infrastructure in developing countries.
Advancement in Drug Delivery Techniques to Provide Manufacturers of Ophthalmic Drugs with Substantial Growth Opportunities

Recent studies have stated that advancements made in the technology of drug delivery techniques are likely to drive the sales of ophthalmic drugs globally. Compared to conventional drug delivery techniques, advanced techniques comprising intraocular implants and nanoscale techniques are stated to have sustained drug delivery and higher bioavailability. These modern nanoscale techniques are beneficial for the diagnosis and treatment of several eye diseases. TMR analysts state that these nanoparticle drugs carry significant growth prospects for companies as they have the potential for innovative uses such as in contact lenses, which would result in optimal bioavailability.

Healthcare Infrastructure Development Initiatives by Governments to Boost Demand for Ophthalmic Drugs

Governments of developing regions are taking initiatives towards creating awareness regarding eye disorders through the development of advanced healthcare infrastructure. For instance, the Indian Government’s initiatives, such as the National Program for Healthcare of the Elderly (NPHCE) and the National Rural Health Mission, are projected to improve the nation’s healthcare services. Similarly, initiatives taken up by governments of other developing countries are likely to boost the demand for ophthalmic drugs in the respective countries. Due to the initiatives taken up by the Brazilian government, the healthcare services in the country have improved substantially and its per capita expense for healthcare was valued at US$1,402 in 2015.

Lack of Proper Health Reimbursement Facilities to Hinder Demand for Ophthalmic Drugs in Developing Nations

Despite the promising prospects created by the proactive stance taken by governments, developing nations such as China and India lack the resources to provide primary healthcare services and health insurance to a large population due to poverty. Statistics published by the WHO stated that in 2013, out of pocket expenditure was much lower in developed countries than in developing countries. This is anticipated to hinder the demand for ophthalmic drugs in developing regions as the expenses in the use of ophthalmic drugs are not covered by reimbursement facilities.

North America is expected to dominate the global ophthalmic drugs market between 2013 and 2018 due to the rise in eye disorders among its aged population. Asia Pacific has been reported to be the fastest growing market, also owing to its large geriatric population. The global ophthalmic drugs market is expected to rise to a market value of US$2.16 bn expected by the end of 2018.

The review has been based on the findings of a TMR report titled “Ophthalmic Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2018.”

Browse Research Report on Global Ophthalmic Drugs Market:

Friday, 5 August 2016

Electronic Health Records Market to Benefit from Government Initiatives to Adopt EHR Systems

As physicians’ around the world adopt information technology to streamline their routine work, it is expected to give a major boost to the global electronic health records solution market. In a report, titled “Electronic Health Records Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023,” Transparency Market Research, provides a holistic overview of the various factors influencing the market. The report has pegged the value of the global electronic health records solution market at US$18.93 bn in 2014. Rising at a CAGR of 5.4%, the market is expected to reach US$30.28 bn by the end of 2023.

Get a Free Sample Report: 

Electronic health records (EHR) provide a summary of medical records generated electronically during a clinical encounter.  An EHR is designed to provide an electronic record of medical history of any patient. These records are maintained by third-party service providers over time. The service providers help clinicians in maintaining key administrative clinical data such as progress notes, demographics, medications, side-effects, vital signs, laboratory data, past medical history, and other information relevant to patient care.

Apart from knowledge about the significant advantages of EHR, financial incentives by governments worldwide are among the prime factors boosting the global EHR solution market. An EHR system provides up-to-date information regarding patients, helps in reducing healthcare cost in the long-term, reduces the chances of medical errors, ensures quick access to data related to patients, increases patient participation, and contributes in improving the overall efficiency of healthcare providers. These advantages are turning healthcare providers in favor of adopting technically advanced EHR systems. Furthermore, favorable policies and financial incentives offered by governments will stimulate the adoption of EHR systems in developing regions.

Based on installation type, the global electronic health records solution market is segmented into client-based servers, web-based services, and software as a service. The rising installation of EHR systems across the healthcare industry can be attributed to the increasing need for enhancing efficiency in patient care, technological advancements prompting data access through smartphones, and the rising disposable income of potential consumers.

Web-based EHR systems have emerged as the most popular solution among medical professionals since they help in reducing the deployment cost. Client-server based EHR system on the other hand require upfront installation fees, which restraints their deployment in small and mid-size practices. Besides this, the software-as-a-service (SaaS) segment is expected to rise at a robust pace during the forecast period. Higher preference for SaaS is noted among physicians since it helps in eliminating technical glitches and has lower upfront costs.

To study the market’s competitive landscape, the report also profiles companies such as CPSI, Cerner Corporation, Allscripts Healthcare Solutions, Inc., GE Healthcare, Medical Information Technology, Inc., Medical Information Technology, Inc., and others.

Browse Research Report on Global Electronic Health Records Solution Market:

Thursday, 4 August 2016

Diabetes Devices and Drugs Market to Reach US$83.0 bn by 2019 due to Introduction of New Insulin Formulations

A new Transparency Market Research report states that the global diabetes devices and drugs market valued more than US$54.0 bn in 2012 and is expected to reach US$83.0 bn by 2019, by rising at a 5.90% CAGR between 2013 and 2019. The title of the report is “Diabetes Devices and Drugs Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019.” 

Diabetes mellitus, commonly known as diabetes, is a group of metabolic disorders wherein either the body isn’t able to produce insulin or isn’t able to use the already generated insulin. The former happens in case of type-1 diabetes and the latter in case of type-2 diabetes. Thus, the raised sugar levels result in a number of symptoms such as weight loss, increased thirst, frequent urination, and high appetite. Diabetes, if left untreated, may cause numerous chronic or acute potentially-fatal complications. Thus, a number of devices and drugs are being introduced for the treatment of diabetes.

As per this report, the rising diabetic population globally and the increasing incidence of chronic diseases as a result of diabetes are amongst the key factors propelling the growth of the market for diabetes devices and drugs. In addition, the continuous activities of research and development have also positively impacted the growth of the market. Furthermore, the rising technological advancements will further augment the development of the market. The introduction of non-invasive diabetes diagnostic and drug delivery devices and the launch of new insulin formulations in the market are the key growth opportunities in the market.

On the other hand, the profitability of players is being hampered by patent expiry and the high cost of treatment and diagnosis. In addition, the unsupportive reimbursement policies will also impact the diabetes devices and drugs market negatively in the forthcoming years.

On the basis of device, the global diabetes devices market is segmented into diabetes monitoring and diagnostic devices and insulin delivery devices. Amongst these, monitoring and diagnostic devices are further segmented into analog glucose meters, glucose test strips, lancets and lancing devices, continuous glucose monitoring devices, and others.

Insulin delivery devices are further segmented into insulin syringes, insulin pens, insulin pumps, and insulin injectors. The segment of continuous glucose monitoring devices is predicted to rise at a 6.60% CAGR between 2013 and 2019. On the other hand, insulin pens are also witnessing substantial demand in the global market.

By therapy, the global diabetes drugs market is segmented into insulin, non-insulin injectable anti-diabetes drugs, and oral anti-diabetes drugs class. Of these, insulin is further segmented into short-acting insulin derivatives, intermediate-acting insulin derivatives, long-acting insulin derivatives, rapid-acting insulin derivatives, and premixed insulin derivatives. The oral anti-diabetes drugs class is further segmented into sulphonylureas, biguanides, meglitinides, thiazolidinediones, alpha-glucosidase inhibitors, DPP-4 inhibitors, and SGLT-2 inhibitors. Non-insulin injectable anti-diabetes drugs are further segmented into GLP-1 analogs.

Geographically, the report segments the market into North America, Europe, Asia-Pacific, and Rest of the World (RoW). Amongst these, North America leads the market for diabetes devices and drugs. This is due to the rising diabetic population, advanced medical infrastructure, and the increasing technological developments within this region.

However, Asia Pacific is projected to be the most lucrative market for diabetes devices and drugs in the forecast horizon. This is owing to the growing occurrence of diabetes and the rising awareness about self-management and monitoring of diabetes in this region.

As mentioned in the study, the prominent players dominant in the market are AstraZeneca plc, Abbott Laboratories, Inc., B Braun Melsungen AG, Becton, Dickinson and Company, Bayer HealthCare AG, Ingelheim GmbH, and Boehringer, among others.

Browse Research Report on Global Diabetes Devices and Drugs Market:

Tuesday, 2 August 2016

Nurse Call Systems Market: To Dominant Market Share, Market to Register 13.90% CAGR 2014-2020

The top five vendors in the global nurse call systems market collectively held 44% of the market in 2013. However, these vendors-Ascom Holding AG, Rauland-Borg Corporation, Tyco SimplexGrinnell, Azure Healthcare Limited, and Hill-Rom Holdings Inc.-have to compete with numerous small-sized players in a highly fragmented landscape. These are the findings of a recent study published by Transparency Market Research (TMR). 

“Acquisitions and takeovers have been the key growth model for companies in the nurse call systems market,” says the author of the study.  A case in point would be Ascom Holding AG, the company acquired Integrated Wireless Software Pty. Ltd. and Integrated Wireless Pty. Ltd. This has allowed the company to penetrate into Asia Pacific and build a strong foothold in this region.

System integration to increase compatibility with various healthcare applications in a bid to offer comprehensive workflow solutions is also what key players in this market are striving for.  The integration of nurse call solutions allows real-time monitoring of individual patient metrics. The formation of national-level dealer networks in order to increase product reach and availability is another strategy adopted by key players in the nurse call systems market.

Demand for High-quality Patient Care Necessitates Installation of Nurse Call Systems

“An increasing geriatric population across the world is a major factor driving the global nurse call systems market,” says a TMR analyst. This is because this population is susceptible to illnesses and may require hospitalization for dedicated care. The use of nurse call systems for the geriatric population ensures that the patient can raise an alert at the nurse’s station to deliver timely care. This, in turn, allows healthcare organizations to attain seamless communication and streamline nursing activities.

The increasing budget allocation for healthcare of the elderly population is also significantly contributing to the growth of this market. With an increase in the median age of the global population, several countries are focused on providing improved healthcare. Factors such as increasing dependency ratio and the retirement of baby boomers have necessitated the availability of quality healthcare services for aged population.

The increasing need for effective and responsive healthcare communication is another significant factor driving the global nurse call systems market. This is because nursing staff need to be watchful and responsive to provide high quality of healthcare and to ensure patient safety.

“Government regulations in place for the manufacture and distribution of nurse call systems is major impediment to the growth of this market”, says TMR analyst. As per the recent amends by the International Medical Device Regulators Forum (IMDRF), nurse call systems would be included in the category of medical devices. This necessitates nurse call systems to be clinically audited, regulated, and certified.

The IMDRF amend also requires that the software within medical devices need to satisfy medical grade ISO 9000 quality control specifications. 

Hospitals Represent Largest End-use Segment

The global nurse call systems market is expected to be worth US$1.57 bn by 2020. Nurse call integrated communication systems is the leading segment of the market on the basis of equipment type; the segment held almost 75% of the overall market in 2013. Nurse call mobile systems equipment type is expected to display significant demand in the foreseeable years. Wired nurse call communication equipment is the largest segment of the market on the basis of communication technology. Hospitals is the largest end-use segment of the nurse call systems market.

Monday, 1 August 2016

Erectile Dysfunction Market to Decline at a CAGR of -4.5% 2013-2019 as Drugs Lose their Patents

Transparency Market Research has recently published a detailed research report on the global erectile dysfunction drugs market. The research report, titled “Erectile Dysfunction Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019,” has studied the market using Porter’s five forces analysis to understand the threat of new entrants, the threat of substitute products or services, the bargaining power of suppliers, the intensity of competitive rivalry, and the bargaining power of customers. Furthermore, it also states the strengths, weaknesses, opportunities, and threats impacting the segments of the overall erectile dysfunction drugs market. 

According to the research report published by Transparency Market Research, the global erectile dysfunction drugs market is likely to plummet in the near future to US$3.4 bn in 2019, from US$4.3 bn in 2012, declining at a negative CAGR of -4.5% from 2013 to 2019. The market is expected to experience a drop in the revenue, as several medicines are poised to reach patent expiration and the marketing exclusivity with it. This is likely to trigger a new hope of establishing a steady revenue flow for generic drug manufacturers as they will have an opportunity to launch their own medicines and brands. Furthermore, the poor success rate of new drugs due to weak pipeline development is also expected to create a drop in the earnings of the global erectile dysfunction drugs market

The global erectile dysfunction drugs market has been segmented on the basis of brand, drugs in the pipeline, and geography. The brands being sold in this market are Viagra (Sildenafil Citrate), Cialis (Tadalafil), Helleva (Lodenafil Carbonate), Levitra/Staxyn (Vardenafil), Zydena (Udenafil), Stendra/Spedra (Avanafil), MUSE (Medicated Urethral System for Erection), and Mvix (Mirodenafil). Some of the major drugs in the pipeline are Vitaros (Alprostadil), Uprima (Apomorphine), and others such as Melanocortin Activators, Topiglan, and Gene Therapy. Geographically, the market is segmented into North America, Europe, Asia Pacific, and Rest of the World.

Despite the negative market sentiment, North America is expected to dominate the global erectile dysfunction drugs market due to the strong presence of topnotch drugs such as Viagra and Cialis in the U.S. all through 2019. According to the report, the North America erectile dysfunction drugs market stood at US$2.1 bn in 2012. The dominance does face certain challenges such as the loss of marketing exclusivity for Cialis (tadalafil) and Levitra/Staxyn (vardenafil) in the coming three years. Furthermore, this market will also be hampered due to the influx of generic drugs, cost containment measures, and introduction of various cheaper products.

Some of the key players in the global erectile dysfunction drugs market are S.K. Chemicals, Bayer AG, Apricus Biosciences, Meda Pharmaceuticals, Dong-A Pharmaceutical, Pfizer, Eli Lilly And Company, and Vivus. The research report profiles these players and offers a comprehensive analysis of the competitive landscape of the global erectile dysfunction drugs market. The report also explains the regulatory framework governing the overall market. Furthermore, the management styles, research and development activities, investment outlook, product portfolio, joint ventures, business and marketing strategies, and strategic mergers and acquisitions of key players have been discussed in this report.

Browse Research Report on Erectile Dysfunction Drugs Market: